Leerink Partnrs Has Negative View of DexCom FY2026 Earnings

DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for DexCom in a research report issued to clients and investors on Thursday, October 24th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings per share of $2.46 for the year, down from their prior forecast of $2.49. The consensus estimate for DexCom’s current full-year earnings is $1.69 per share. Leerink Partnrs also issued estimates for DexCom’s FY2027 earnings at $2.77 EPS and FY2028 earnings at $3.14 EPS.

Several other brokerages also recently commented on DXCM. Oppenheimer dropped their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Morgan Stanley dropped their price target on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, July 26th. BTIG Research decreased their price objective on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. UBS Group lowered their target price on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Finally, Leerink Partners cut their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Six investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Trading Up 0.2 %

NASDAQ DXCM opened at $72.24 on Monday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a market capitalization of $28.73 billion, a PE ratio of 46.61, a P/E/G ratio of 2.26 and a beta of 1.18. The stock has a 50-day simple moving average of $69.98 and a 200 day simple moving average of $96.73.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several hedge funds have recently added to or reduced their stakes in the business. Team Hewins LLC increased its stake in shares of DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after buying an additional 83 shares during the period. Bleakley Financial Group LLC increased its position in DexCom by 1.3% during the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after purchasing an additional 87 shares during the period. Capital Insight Partners LLC raised its holdings in DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares during the last quarter. HM Payson & Co. lifted its position in shares of DexCom by 6.0% in the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after purchasing an additional 100 shares during the period. Finally, State of Alaska Department of Revenue boosted its stake in shares of DexCom by 0.3% in the 1st quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock valued at $5,801,000 after purchasing an additional 105 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.